Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
17.30
+0.61 (3.65%)
Nov 2, 2026, 4:00 PM EST - Market closed
Dyne Therapeutics Employees
Dyne Therapeutics had 289 employees as of June 30, 2026. The number of employees increased by 83 or 40.29% compared to the same quarter last year. That makes Dyne Therapeutics the 24,110th largest employer in the world and 3,103rd in the United States.
Employees
289
Change (1Y)
83
Growth (1Y)
40.29%
Revenue / Employee
n/a
Profits / Employee
-$1,797,249
Market Cap
3.23B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 289 | 83 | 40.29% |
| Mar 31, 2026 | 263 | 71 | 36.98% |
| Dec 31, 2025 | 258 | 67 | 35.08% |
| Sep 30, 2025 | 240 | 67 | 38.73% |
| Jun 30, 2025 | 206 | 54 | 35.53% |
| Mar 31, 2025 | 192 | 49 | 34.27% |
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Sep 30, 2024 | 173 | 37 | 27.21% |
| Jun 30, 2024 | 152 | 18 | 13.43% |
| Mar 31, 2024 | 143 | 21 | 17.21% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Sep 30, 2023 | 136 | 21 | 18.26% |
| Jun 30, 2023 | 134 | 26 | 24.07% |
| Mar 31, 2023 | 122 | 26 | 27.08% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Sep 30, 2022 | 115 | 27 | 30.68% |
| Jun 30, 2022 | 108 | 37 | 52.11% |
| Mar 31, 2022 | 96 | 40 | 71.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Nurix Therapeutics | 317 |
| Viridian Therapeutics | 252 |
| Celcuity | 155 |
| IDEAYA Biosciences | 145 |
| Parabilis Medicines | 145 |
DYN News
- 5 days ago - Oppenheimer downgrades Dyne Therapeutics as vHOT uncertainty reduces confidence - TheFly
- 5 days ago - Dyne Therapeutics downgraded to Perform from Outperform at Oppenheimer - TheFly
- 11 days ago - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Dyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright - TheFly
- 4 weeks ago - Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - GlobeNewsWire
- 4 weeks ago - Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval - TheFly
- 5 weeks ago - Dyne Therapeutics management to meet with Piper Sandler - TheFly
- 6 weeks ago - Dyne Therapeutics Transcript: 2026 Global Healthcare Conference - Transcripts